Uscom

ASX MEDIA RELEASE

Uscom Partners with UTAS in IDEAL eHealth Initiative

SYDNEY, Australia, Wednesday 8th April 2020: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) today announced execution of a partnership with the University of Tasmania as part of the NHMRC funded IDEAL study. The IDEAL study is supported by a $1m AUD NHMRC grant to develop improved methods for monitoring cardiovascular health delivery in Australia, and includes the Uscom BP+ as the front-end blood pressure sensor in this eHealth study.

The International Society of Hypertension estimates the global cost of uncontrolled BP is in excess of $500B, and the IDEAL study is targeting the benefits of early detection and improved management of cardiovascular disease using BP+, an eHealth platform, and novel clinical algorithms. Partners in the collaboration include the University of Tasmania, the Menzies Institute, the National Heart Foundation, the Department of Health Tasmania, Primary Health Tasmania and Healthcare Software.

The study involves patient examination with the BP+ and a cardiovascular risk assessment including completion of a risk profiling questionnaire, and blood sample collection and cholesterol assessment at pathology service centres. The data is recorded on novel clinical software and is securely transferred to the UTAS database for analysis. The Uscom BP+ being used in the IDEAL partnership is currently in use with researchers and influencers at Imperial College, University College and Great Ormond Street Hospital in London, The University of Mons in Belgium, The University of Pennsylvania and Colombia University (New York) in USA, Auckland University, and other major US technology companies.

Uscom has continuing relationships with key decisionmakers and policy influencers for BP guidelines globally including Australia, New Zealand, UK and the USA, including in the special population group of maternal hypertensions. The IDEAL partnership outcomes will be shared among collaborators across disciplines and institutions to help drive adoption of improved global clinical cardiovascular risk stratification and management.

In addition to being included as the lead BP technology in this new eHealth clinical treatment algorithm, Uscom will work with partners to develop and integrate new waveform analysis approaches into current and future products and practice.

The Uscom BP+ has CE and TGA approval, and is currently progressing through Chinese NMPA and US FDA regulatory processes, and is due for international release in 2020.

Executive Chairman of Uscom, Professor Rob Phillips said “The BP+ is perfectly suited to the IDEAL study. While eHealth is leading the new era of clinical care, its application depends on the quality of the patient sensors and BP+ provides new and improved data on the blood pressure, all information that increases the strength of the study. Uscom has invested the last 15 years of product development in optimising core sensors and now has sector leading digital technologies that are “ideal” for monitoring cardiac, vascular and pulmonary care. We currently work with some of the world’s largest technology companies in the development of home care eHealth models for managing heart failure, hypertension, and asthma and COPD. The potential mortality, morbidity and cost savings in getting eHealth right are almost inestimable, and BP+ is an emerging device in that new health practice.”

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases and are platform technologies for eHealth

applications. The USCOM 1A provides vital guidance for optimising of sepsis and fluid, inotropes and vasoactive therapies in hypertension and heart failure monitoring. The BP+ SpiroSonic devices improve diagnosis and management of hypertension, heart failure, asthma, COPD and sleep disorders in the clinical and home care environments.

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.
The USCOM 1A: A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.
The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter, an stand alone software solution and digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary SpiroReporter, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse spirometry outputs and generate summary reports.
For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillip
Executive Chairman

rob@uscom.com.au

Brett Crowley
Company Secretary